Adial Pharmaceuticals(ADIL) - 2025 Q4 - Annual Results

Financial Performance - Cash and cash equivalents were $5.9 million as of December 31, 2025, compared to $3.8 million as of December 31, 2024, indicating a 55.3% increase year-over-year[14] - Research and development expenses decreased by approximately $609 thousand (19%) during the year ended December 31, 2025, compared to the previous year, primarily due to lower clinical activity[14] - General and administrative expenses increased by approximately $125,000 (2%) during the year ended December 31, 2025, mainly due to higher compensation expenses[14] - Net loss was $8.0 million for the year ended December 31, 2025, a decrease from a net loss of $13.2 million for the year ended December 31, 2024, reflecting a 39% improvement[14] Strategic Partnerships and Collaborations - Adial secured U.S. manufacturing supply partnerships with Cambrex and Thermo Fisher Scientific to support late-stage development and future commercialization readiness[3] - Adial entered into a collaboration framework agreement with Molteni Farmaceutici for the commercialization of AD04 in Europe, with a total potential value estimated at nearly $60 million[6][7] Regulatory and Development Progress - The company received a positive response from the FDA regarding its proposed in vitro bridging strategy and successfully completed its End-of-Phase 2 meeting, advancing regulatory alignment toward Phase 3 development[4] - The recent FDA policy discussions indicate a potential shift toward more flexible development frameworks, which could reduce late-stage clinical development costs by tens of millions of dollars[5] Intellectual Property and Market Position - The company strengthened its intellectual property portfolio with multiple U.S. patents issued and filed a PCT application to extend international exclusivity by 14 years through at least 2045[4][10] - The company is well positioned to execute its mission of delivering meaningful treatments for patients impacted by Alcohol Use Disorder (AUD) with an expanded intellectual property estate and strategic partnerships[5]